MindImmune Therapeutics
About MindImmune - MindImmune Therapeutics, Inc. is a privately held drug discovery company founded in 2016 by veteran central nervous system drug discovery scientists Stevin Zorn, Ph.D., Frank Menniti, Ph.D., Robert Nelson, Ph.D., and Brian Campbell, Ph.D., formerly colleagues within Worldwide Research & Development at Pfizer. The company aims to develop first-in-class therapeutics that target the immune system to treat disorders of the central nervous system, targeting conditions such as Alzheimer's disease, Huntington's disease, depression, and neuropathic pain. MindImmune scientists are at the forefront in recognizing therapeutic opportunities in neuroimmunology and have extensive track records of success in neuroscience-based pharmaceutical research and development. Based at the University of Rhode Island, MindImmune benefits from an affiliation with the George & Anne Ryan Institute for Neuroscience, Kingston, RI. Seed financing has been provided by the Slater Technology Fund, Providence, RI and private investors. The photo banner on this page is an image of microglia (green) and neurons (red) in mouse cortex. Courtesy of the Dailey Lab, University of Iowa (www.dailey-lab.com).